|
US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
|
18 October 2018 |
|
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
|
25 September 2018 |
|
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
|
17 September 2018 |
|
Tezepelumab granted Breakthrough Therapy Designation by US FDA
|
07 September 2018 |
|
Selumetinib granted orphan designation in Europe for neurofibromatosis type 1
|
09 August 2018 |
|
Atacand to be divested to Cheplapharm in Europe
|
24 July 2018 |
|
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease
|
12 June 2018 |
|
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline
|
24 May 2018 |
|
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
|
11 May 2018 |
|
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets
|
07 May 2018 |